Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Clinical trial NCT07175051 · RECRUITING

Trial details

NCT number: NCT07175051
Sponsor: University of Illinois at Chicago
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)Albuminuria

Start date: 2026-04-08
Primary completion: 2029-10-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.